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Abstract
Purpose—Polycyclic aromatic hydrocarbons (PAH)-DNA adducts have been associated with 
breast cancer incidence. Aberrant changes in DNA methylation may be an early event in 
carcinogenesis. However, possible relations between PAH-DNA adducts, methylation and breast 
cancer are unknown. The objectives of this study were to (1) assess associations between PAH-
DNA adducts and breast cancer, stratified by DNA methylation markers; and, (2) to examine 
interactions between adducts and DNA methylation in association with breast cancer and tumor 
subtype.
Methods—In a population-based case-control study, promoter methylation of 13 breast cancer-
related genes was measured in tumor tissue (n=765-851 cases). Blood DNA from breast cancer 
cases (n=873) and controls (n=941) was used to assess PAH-DNA adducts and global 
methylation. Logistic regression was used to estimate adjusted odds ratios (ORs) and 95% 
confidence intervals (CI); and the ratio of the OR (ROR) was used to assess heterogeneity.
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Results—Women with detectable PAH-DNA adducts and methylated RARβ (ROR=2.69, 95%CI 
1.02-7.12; p for interaction=0.03) or APC (ROR=1.76, 95%CI 0.87-3.58; p for interaction=0.09) 
genes were more likely to have hormone receptor-positive tumors than other subtypes. Interactions 
with other methylation markers were not apparent (p≥0.10). The association between adducts and 
breast cancer did not vary by methylation status of the tumor nor did adducts associate with global 
methylation in the controls.
Conclusions—Gene-specific methylation of RARβ, and perhaps APC, may interact with 
PAHDNA adducts to increase risk of hormone receptor-positive breast cancer. There was little 
evidence that adducts were associated with or interacted with other methylation markers of 
interest.
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Breast cancer is the most commonly diagnosed cancer among women in the United States 
(US), excluding non-melanoma skin cancer [1]. Polycyclic aromatic hydrocarbons (PAHs) 
are one of the few environmental exposures to be linked to breast cancer risk in several 
epidemiological studies [2-5] and induce mammary tumors in laboratory animals [6]. PAHs 
form during combustion of organic material [7]. Major ambient, PAH sources include 
tobacco smoke, diet and indoor and outdoor air pollution [7].
PAH-DNA adducts are a biomarker of PAH exposure, the measurement of which reflects 
the resulting level of DNA damage and thus represents the effective biological PAH dose 
[8]. PAH-DNA adducts generally represent exposures ranging in the preceding few months 
to few years due to high cell turnover rates [5]. However, PAHs are lipophilic compounds 
and can be stored in adipose tissue and consequently be released over time [3].
Aberrant DNA methylation, both global and gene-specific, has been shown previously to be 
relevant to breast carcinogenesis [9-11]. Decreased global methylation is hypothesized to be 
associated with increased genomic instability and mutation rates [12]. Previously, we 
reported an increase in risk with breast cancer for luminometric methylation assay (LUMA), 
but not for methylation of long interspersed elements-1 (LINE-1) in white blood cells [9]. In 
contrast, increased methylation of tumor suppressor genes, typically indicative of the gene 
being ‘silenced,’ has been considered to be relevant to cancer incidence [13] and has been 
demonstrated to be associated with breast cancer clinical/pathological factors and mortality 
in this study population [14]. Previous research has found that exposure to PAH may be 
associated with changes in DNA methylation [15-17].
While both PAH-DNA adducts and aberrant DNA methylation are known to be relevant to 
breast cancer, no previous research has investigated their potential interaction with breast 
cancer incidence. DNA methylation may promote spontaneous deamination, enhance DNA 
binding of carcinogens such as PAH, and increase ultraviolet absorption by DNA; all 
mechanisms that may result in increased DNA adduct formations and gene inactivation [18]. 
Thus, it is biologically plausible that PAH-DNA adducts and methylation may have a 
synergistic impact on breast carcinogenesis.
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In this same study population, we have previously reported an OR of 1.29 (95%CI 1.05, 
1.58) for the association between breast cancer incidence and detectable PAH-DNA adducts 
relative to women with non-detectable adducts [4]. For this current study, we first aimed to 
further examine the association between PAH-DNA adducts and breast cancer incidence by 
stratifying by the promoter methylation status of a panel of 13-breast cancer related genes 
(APC, BRCA1, CCND2, CDH1, DAPK1, ESR1, GSTP1, HIN1, CDKN2A, PGR, RARβ , 
RASSF1A and TWIST1), measured in the tumor tissue of cases. These 13 genes were chosen 
because of their established roles in breast carcinogenesis [11]. The promoters of steroid 
hormone genes (ESR1,PGR, RARβ) and tumor suppressors (BRCA1, APC, CDKN2, HIN1, 
CDH1, RASSF1a, DAPK1) are often hypermethylated in breast tumor tissues and 
methylation of these genes has been associated with malignancy and survival [19-28]. 
Hypermethylation at the promoter region is hypothesized to be the cause, or at least a 
marker, of loss of gene function [11]. We also investigated whether PAH-DNA adducts 
were associated with global methylation in controls, using two independent global 
methylation markers, LINE-1 and LUMA, measured in blood DNA. Further, we 
investigated the possibility of effect measure modification between PAH-DNA adducts and 
DNA methylation with breast cancer and tumor heterogeneity by hormone receptor status.
Materials and Methods
The investigation detailed here builds upon existing population-based resources from the 
Long Island Breast Cancer Study Project (LIBCSP). The parent LIBCSP methods have been 
previously reported in detail [29]. Institutional Review Board approval was obtained 
Institutional Review Board (IRB) approval was obtained from UNC-CH, Columbia 
University and Mt. Sinai Medical Center.
Study Population
For our DNA gene-specific methylation approach, our study draws primarily upon data 
collected from the case participants of the LIBCSP; and for global methylation, our study 
draws upon data from both the LIBCSP cases and controls. The LIBCSP cases and controls 
were English-speaking women residing in Nassau and Suffolk counties on Long Island, New 
York.
Cases were women who had been recently diagnosed with a first primary in situ or invasive 
breast cancer between August 1st, 1996 and July 31st, 1997, were eligible as cases. Cases 
were identified using rapid case ascertainment via daily/weekly contact with pathology 
departments of all 28 hospitals on Long Island and three tertiary care hospitals in New York 
City. Breast cancer diagnoses were confirmed by the physician or the medical record.
Controls were women with no previous history of breast cancer, and residents of either 
Nassau or Suffolk counties in 1996-1997, were eligible as controls. Controls were frequency 
matched in 5-year age groups to cases based on the expected age distribution of case 
women. Controls were identified using random digit dialing for those who were less than 65 
years of age, and for those who were 65 years of age and greater, using the Health Care 
Finance Administration rosters.
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Parent study participants included 1,508 cases and 1,556 controls (82% and 62.7%, 
respectively, of all eligible subjects), who completed the structured, epidemiologic 
questionnaires administered by trained interviewers, shortly after diagnosis or identification. 
Written informed consent was obtained from all study participants prior the interview and 
blood collection. Participants ranged in age from 20-98 years and 67% were postmenopausal 
at the time of diagnosis for cases, and time of identification for controls; and 94% reported 
their race as white, 4% as black, and 2% as other, which is consistent with the underlying 
racial/ethnic distribution in these two NY counties at the time of data collection.
Exposure Assessment
PAH-DNA adducts—The assessment of PAH-DNA adducts, and the modest positive 
association observed between these adducts and breast cancer risk has been previously 
published [5,4]. Briefly, 73.0% of cases and 73.3% of controls who completed the 
questionnaire donated nonfasting blood samples, approximately three months after diagnosis 
for cases (and thus prior to chemotherapy for 77.2%) and six months after identification for 
controls. These samples were then shipped overnight at room temperature to Columbia 
University in New York City. Samples were processed and stored at −80°C. DNA was 
extracted from blood samples and was used to assess PAHDNA adduct levels in 
mononuclear cells by competitive enzyme-linked immunosorbent assay (ELISA). 
Laboratory assays of the PAH-DNA adduct was successfully completed for 873 cases and 
941 controls [4]. The limit of detection for the ELISA assay was defined as <15% inhibition 
[5]. PAH-DNA adducts were defined as detectable versus non-detectable as previous study 
findings [5,4] did not support a dose-response association.
Gene-specific promoter DNA methylation assessment—Promoter methylation 
status was measured in tumor tissue for a panel of 13 breast cancer-related genes (APC, 
BRCA1, CCND2, CDH1, DAPK1, ESR1, GSTP1, HIN1, CDKN2A, PGR, RARβ , 
RASSF1A and TWIST1). These genes are known to play an important role in breast 
carcinogenesis and their promoter regions are frequently methylated in breast tumor tissues 
[11].
The methods used to determine gene-specific promoter methylation levels have been 
previous published and are briefly described below [9,11]. Tumor blocks were acquired and 
DNA was extracted as described in previously published methods [30].To determine gene-
specific promoter methylation levels for ESR1, PGR and BRCA1, methylation-specific PCR 
was used [30,31]. DNA was considered methylated if PCR product was yielded using the 
methylation-specific primers. This produces a dichotomous outcome, methylated or not 
methylated. Thus, ESR1, PGR and BRCA1 are dichotomous variables (methylated vs. 
unmethylated) as determined by the assay. The MethyLight assay was used to measure the 
methylation status of the remaining genes [32,33]. Genomic bisulfite-converted DNA is 
amplified by fluorescence-based, real-time quantitative PCR which provides a quantitative 
assessment of percentage methylated [34,35]. Number of samples completed and percent 
methylated for each promoter in LIBCSP has been reported; number of samples ranges 
between n=765 and n=851 and percent methylation ranges between 3.6% and 62.9% [11]. 
Continuous values were dichotomized (<4%, ≥4% methylated) to be consistent with 
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previous published reports by our study team and others [11,33]. This methylation cutpoint 
has been found to best distinguish between malignant and normal tissues as well as to 
indicate repressed gene expression when using the MethyLight assay [36,37].
Global Methylation Assessment—As previously described [9], two independent, but 
complimentary, methods were used to assess global methylation levels in DNA extracted 
from blood samples: (1) the analysis of LINE-1, which is an approximate measure of 
methylation levels in repetitive elements or transposons; and, (2) LUMA, which measures 
levels of 5-mC in the ‘CCGG’ sequence frequently found in gene promoters. For both 
LINE-1 and LUMA, methylation assessment was completed for 1,055 cases and 1,101 
controls.
The LINE-1 assay was completed using a prevalidated pyrosequencing assay to assess 4 
CpG sites in the promoter of LINE-1 at EpigenDx (Worcester, MA, USA) as described 
previously [9]. Methylation status at each of the 4 CpG loci was analyzed individually as a 
T/C single nucleotide polymorphism (SNP) using QCpG software (Qiagen). Methylation 
status data at all 4 loci were averaged to provide an overall percent 5-mC status. The 
methods used for the LUMA assay in LIBCSP has been previously described [9]. This 
method has been previously validated using samples with known DNA methylation levels 
[38]. LUMA methylation level is expressed as a percentage obtained using the following 
equation [38]: methylation (%) = ((1-(HpaII∑G/∑T)/ (MspI∑G/∑T) * 100)). For LUMA 
quality control, cases and controls were assayed at the same time and laboratory personnel 
were blinded. Randomly selected samples were replicated to examine potential batch effects 
and to determine any variation between different runs and the percent corresponding inter-
individual variability (CV) was less than 1%.
Hormone receptor subtype—We abstracted data recorded on the medical record to 
ascertain breast cancer subtype defined by hormone receptor status [29]. Estrogen and 
progesterone receptor status (ER/PR) of the first primary breast cancer was available from 
the medical record for 990 cases (65.6%).
Statistical Analysis
All analyses were completed using SAS 9.3 (Cary, NC).
Gene-specific promoter methylation—To investigate whether PAH-DNA adducts 
(detectable/nondetectable) were associated with breast cancer, stratified by gene-specific 
promoter methylation levels measured in case tumor tissue, we used a case-control 
approach. Polytomous logistic regression [39] was used to estimate ORs and ratio of the 
odds ratios (RORs) with corresponding 95%CIs with the case groups determined by tumor 
methylation status.
To assess whether PAH-DNA adducts and gene-specific methylation interacted to influence 
the development of hormonally-defined breast cancer subtypes, we utilized both a case-case 
[40] and a case-control approach [39]. First, we assessed whether the association between 
PAH-DNA adducts and ERPR status varied across methylation group, by evaluating the 
multiplicative interaction between adducts and gene-specific promoter methylation using a 
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case-case approach. We estimated the association between detectable PAH-DNA adducts 
and tumor subtype within strata of gene-specific promoter methylation using a case-control 
approach to calculate ORs and 95%CI. We also estimated RORs and 95%CIs for the 
association between PAH-DNA adducts with breast cancer characterized by tumors subtype, 
stratified by gene-specific promoter methylation [41]. We considered two definitions for the 
outcome, tumor subtype: (1) hormone receptor positive (ER+PR+) tumors compared to all 
other subtypes (ER-PR-, ERPR+, ER+PR-) and; (2) hormone receptor negative (ER-PR-) 
tumors compared to all other subtypes (ER+PR+, ER-PR+, ER+PR-). When using a case-
case approach in this scenario, the ROR is an estimation of the likelihood of a certain tumor 
subtype given the combined methylation status and PAHDNA adduct level and can be 
interpreted as a measure of heterogeneity [40] as well as a measurement of the interaction on 
the multiplicative scale [42]. If the gene-specific promoter sample size within strata was less 
than 5, it was no longer considered. Multiplicative interaction was assessed by comparing 
polytomous regression models (outcome defined as 0=controls, 1=unmethylated cases, 
2=methylated cases) with and without cross-product terms to denote the interaction between 
adducts and the individual methylation marker using an a priori alpha level of 0.10 [41]. A 
significant interaction indicated that the odds of having a certain tumor type, given PAH-
DNA adduct level, is statistically different across strata of tumor methylation.
Global Methylation—We used a controls-only approach to assess whether PAH-DNA 
adducts (detectable vs. nondetectable) are associated with global methylation levels 
measured in the blood of controls only. We limited to controls as cases may have lower 
global methylation levels [12]. We conducted unconditional logistic regression to estimate 
odds ratios (ORs) and 95% confidence intervals (CI) [41], with global methylation markers 
as the outcome. LINE-1 and LUMA levels were dichotomized based on the distribution 
among controls.
We use a case-control approach to assess whether PAH-DNA adducts interact with global 
methylation global methylation (LUMA and LINE-1) to influence breast cancer risk. We 
conducted unconditional logistic regression [41] among cases and controls. Multiplicative 
interaction was assessed by comparing multivariable models with and without cross-product 
terms to denote the interaction between adducts and the individual methylation marker using 
an a prior alpha level of 0.10 [41]. To explore heterogeneity of the estimates for the 
interaction between global methylation markers and PAHDNA adducts across breast cancer 
subtype we used a case-case approach [40].
Confounders—Potential confounders considered included age at diagnosis, age at 
menarche (continuous), body mass index (weight in kilograms/height in meters squared, 
continuous), lactation (yes, no), income (<$15,000, $15,000-$19,000, $20,000-$24,999, 
$25,000 - $34,999, $35,00-$49,999, $50,000-$69,999, $70,00-$89,000, ≥$90,000), active/
passive smoking history (no active nor passive, active but no passive, passive but not active, 
active and passive), and average lifetime intake of grilled and smoked food (servings per 
year, quintiles). Confounders were included in the model if they were significantly 
associated with PAH-DNA adducts or the methylation marker and if they changed the 
White et al. Page 6













estimate by greater than 10%. Using this criterion, only 5-year age group remained in the 
models as a confounder; thus all models include 5-year age group.
Sensitivity Analyses
Approximately three-quarters of the cases had not undergone chemotherapy prior to blood 
sample. We conducted a sensitivity analysis restricting to cases who gave blood prior to 
chemotherapy.
Results
The age distribution of the LIBCSP study population by case status and PAH-DNA adduct 
levels is shown in Table I.
Gene-Specific Promoter Methylation
The association between detectable PAH-DNA adducts and breast cancer, stratified by the 
13 gene-specific promoter methylation levels in case tumor tissue is displayed in Table II. 
Cases with detectable adducts were less likely to have a methylated HIN1 gene(ROR=0.66, 
95%CI 0.42-1.05), although the confidence intervals included the null value and the 
interaction was not statistically significant (p ≥ 0.10). The remaining 12 gene-specific 
promoter methylation levels did not appear to impact the association between detectable 
PAH-DNA adducts and breast cancer incidence.
We hypothesized that PAH-DNA adducts and gene-specific promoter methylation levels 
may interact to influence the likelihood of developing hormonally-responsive breast cancer. 
While these associations are limited by the low prevalence of these methylated markers in 
our hormone-responsive case population, we did find evidence of a multiplicative 
interaction with methylation of RARβ (p=0.03), and APC (p=0.09). The association between 
PAH-DNA adducts and ER+PR+ tumor subtype by promoter methylation levels are shown 
in Table III. When compared to controls, cases with detectable PAH-DNA adducts and 
methylated RARβ or APC were more likely to have hormone receptor-positive breast cancer 
(RARβ, OR=2.15, 95%CI 1.03-4.47; APC, OR=1.59, 95%CI 0.98-2.58) than to have other 
tumor subtypes (RARβ, OR=0.80, 95%CI 0.41-1.56; APC, OR=0.91, 95%CI 0.52-1.58). 
Thus, the joint association of PAH-DNA adducts and methylation of these two genes varied 
across tumor subtypes (ER+PR+ vs all others, RARβ, ROR=2.69, 95%CI 1.02-7.12; APC, 
ROR=1.76; 95%CI 0.87-3.58). Conversely, women without a methylated RARβ or APC 
were less likely to develop ER+PR+ breast cancer compared to other subtypes (RARβ, 
ROR=0.79, 95%CI 0.42-1.46; APC, ROR=0.73, 95%CI 0.35-1.53).
The interaction between detectable adducts and methylation of RARβ was robust and 
remained significant when ER+PR+ tumors were compared to ER-PR- tumors alone (p 
interaction=0.05); however, the interaction with APC was no longer significant (p 
interaction =0.7). Further, no three-way interaction was observed between age, gene specific 
methylation and PAH-DNA adducts suggesting that age did not drive this association (APC, 
p interaction=0.7; RARβ, p for interaction=0.5). We did not observe interactions with the 
remaining six gene promoters when using a case-case approach (p ≥ 0.10) (Table III). 
Although not a significant interaction as defined by our a priori criteria, we did observe a 
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similar trend with the gene promoter GSTP1; with an elevated association with ER+PR+ 
tumors among women with detectable adducts and a methylated GSTP1 (Table III). When 
investigating potential interaction between adducts and methylated genes in association with 
ER-PR- breast cancer, we did not find any evidence of significant multiplicative interaction 
for the five gene promoters tested (p ≥ 0.10) (Table IV).
Global Methylation
Using a control-only approach, detectable PAH-DNA adducts were modestly associated 
with LINE-1 methylation (OR=1.25, 95%CI 0.94-1.65), but not with LUMA methylation 
levels (OR=0.92, 95%CI 0.70-1.22); however, confidence intervals for both effect estimates 
included the null value (Table V). Using a case-control approach, we investigated potential 
interaction, between PAH-DNA adducts and global DNA methylation (either LINE-1 or 
LUMA), in association with breast cancer risk, but did not observe evidence of interactions 
on the multiplicative or additive scales (Supplemental Table I). We additionally 
investigated, using a case-case approach, interactions between PAH-DNA adducts and 
LUMA when considering breast cancer tumor subtype, and found no evidence of interaction 
(Supplemental Table II).
Sensitivity analyses
When we restricted our analyses to women who donated blood prior to chemotherapy, our 
results remained similar (data not shown).
Discussion
In our population-based study, we observed interactions between PAH-DNA adducts and 
select gene-specific promoter methylation levels with hormone-receptor positive breast 
cancer tumor subtype. Although our conclusions are limited by the number of subjects with 
positive PAH-DNA adducts and DNA methylation, we found that women with detectable 
adducts and methylated RARβ or APC genes were more likely to have ER+PR+ breast 
cancer compared to other subtypes. We also found that detectable PAH-DNA adducts were 
associated with HIN1 methylation in tissue of cases and LINE-1 in blood of controls, 
although the confidence intervals included the null value. In contrast, we did not find 
evidence that the association between PAH-DNA adducts and breast cancer incidence was 
modified by global DNA methylation markers. Further, we found little evidence that the 
other methylation markers of interest interacted with PAH-DNA adducts to influence breast 
cancer incidence or tumor subtype. To our knowledge, this is the first study to investigate 
potential interactions of global and gene-specific methylation with the relationship between 
PAH-DNA adducts and breast cancer.
Findings from previous studies suggest that breast cancer may have distinct patterns of CpG 
island methylation according to subtypes [14]. RARβ is an established target for silencing by 
epigenetic modifications in tumor as part of an early event of carcinogenesis [43]. Our 
results suggest that epigenetic inactivation of tumor suppressor genes, in particular RARβ 
and APC, may interact with PAH-DNA adducts, to influence hormone receptor status of the 
tumor. Thus, DNA methylation patterns may result in an increased susceptibility to certain 
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breast cancer tumor subtypes given exposure to PAH. However, the mechanism for this 
relation is not elucidated and requires replication in other study populations. APC has been 
shown in cell lines to have a role in DNA repair [44]. Silencing of APC via DNA 
methylation may thus impact the efficiency of DNA repair processes. Functioning DNA 
repair is very important in the presence of PAH-DNA adducts and not correcting this 
damage could lead to breast carcinogenesis [6]. Additionally, methylation at APC has 
previously been found to correlated with ER positivity in tumor tissue [45] and methylation 
of RARβ has been correlated with PR positivity in the LIBCSP [14]. Additional information 
on the interplay between environmental exposures and epigenetic variation by breast tumor 
subtype may provide a better understanding of molecular differences. We did not observe 
interactions with the 11 remaining genes considered in this study, many of which, such as 
GSTP1, are known to be relevant to breast cancer and metabolism of PAHs [46]. The low 
prevalence of these methylation biomarkers in our study sample may have contributed to our 
inability to detect modest interactions.
In our LIBCSP cases detectable PAH-DNA adducts were found to be possibly associated 
with HIN1 promoter methylation levels but not any of the other remaining 12 genes. 
Although limited, previous studies have reported that both hyper- and hypomethylation of 
tumor suppressor genes are associated with DNA adducts [47,17]. For example, one study 
reported IL-6 hypermethylation and p53 hypomethylation to be correlated with anti-
benzo[a]pyrene diol epoxide-DNA adduct levels [48]. Therefore, any associations between 
adducts and gene-promoter methylation is likely site-specific.
Methylation frequencies may vary based on factors such as laboratory assay, progression of 
the tumor and demographics such as race [49]. Lewis et al. 2005 reported the frequency of 
methylation in tumor tissues to be about 57% for APC and about 59% for RASSF1a when 
using methylation-specific PCR in a small convenience sample of US women (n=38 breast 
cancer cases) [50]. Another clinic-based study of women in Turkey (n=40 breast cancer 
cases) measured methylation using MethyLight assay and found frequencies to be 18% for 
BRCA1, 75% for HIN1%, 83% for RASSF1a, 23% for CDH1, 25% for RARB, 53% for APC, 
18% for TWIST and 30% for CCND2 [51] . In LIBCSP (n=765-851 breast cancer cases), 
methylation frequencies were 48% for APC, 85% for RASSF1a, 59% for BRCA1, 63% for 
HIN1, 6% for CDH1, 28% for RARB, 15% for TWIST and 20% for CCND2 [11]. So, the 
frequencies of certain methylation sites are similar across studies, including our own much 
larger population-based study, but there is some variability, which could be due to 
differences in the populations that were sampled as well as the laboratory methods 
employed.
Some promoter methylation is necessary in order to maintain normal cell function and 
studies that measure gene-specific methylation in tissue of women without breast cancer do 
report lower frequencies of methylation. One study found that women with breast cancer 
were more likely to have methylation at RARβ2, RASSF1a, CCND2, APC compared to 
normal breast tissue among women without breast cancer [50]. They also reported that the 
likelihood of having two or more methylated genes was significantly higher in cancer tissue 
compared to the normal breast tissue of women without breast cancer [50]. Similarly, 
Fackler and colleagues reported methylation levels of RASSF1a, Cyclin D2, HIN1 and 
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TWIST were higher in malignant breast tissues compared to adjacent normal tissue among 
women with breast cancer [27]. It is generally accepted that the highest methylation levels 
occur in the malignant tissue, followed by normal tissue adjacent to the malignancy, and that 
women without breast cancer have the lowest levels. Thus, any case-control results or results 
from comparing malignant vs. adjacent tissue in the same woman, would yield 
underestimates of a true methylated vs. unmethylated tissue comparison. Consequently, the 
case-case comparisons may better reflect truth, because we actually have measured 
methylation levels in the tissue of all case women. Hence, we only present results from case-
case comparisons for this study.
Hypothesized to represent decreased genomic integrity, LINE-1 hypomethylation may be 
associated with cancer, including breast cancer [12]. However, LINE-1 hypomethylation 
was not found to be significantly associated with breast cancer in the LIBCSP [9], and a 
recent meta-analysis concluded there was no association with LINE-1 and overall cancer 
risk [12]. As shown in our supplementary information, PAH-DNA adducts were imprecisely 
associated with LINE-1 hypermethylation in our population-based sample of ambiently 
exposed women, but not LUMA. A study of prolonged B[a]P exposure in mouse embryonic 
fibroblasts found global DNA hypermethylation was associated with DNA-
methyltransferase overexpression [52]. DNMTs bind to DNA lesions with high affinity 
when there is high DNA damage [53], which might explain at least in part this result of 
increased methylation of LINE-1 in association with adduct levels reported here and in other 
studies [54,48,47].
A strength of our study is its population-based design, where we recruited women newly 
diagnosed with a first primary breast cancer in a single year who were residents of a 
prescribed geographic area. Additionally, it was conducted in women who were ambiently 
exposed to PAH [29,5], a group that is often understudied because of the challenges with 
identifying associations in lower exposed individuals. We were also able to utilize the 
extensive resources of the LIBCSP, including tumor subtype information, and were able to 
take into account both global and gene-specific DNA methylation. Despite being the largest 
study to investigate this research question to date, estimates, especially in the case-case 
analysis, had wide confidence intervals. Therefore, future studies would benefit from a 
larger sample size to more precisely estimate some potentially modest associations between 
the gene-specific promoter methylation with tumor subtype. Similarly, although we 
investigated more DNA methylation markers than any other study to date, future studies 
would benefit from including additional markers, which may play a role in the association 
between PAH-DNA adducts and breast cancer. Due the use of methylation-specific PCR for 
ESR1, PCR and BRCA1, which is less sensitive than the MethyLight assay, we may have not 
been able to detect very low levels of methylation for these genes. We did not adjust for 
multiple comparisons in this study; as such, we did not rely heavily on statistical 
significance in the interpretation of the results and all comparisons were driven by previous 
hypothesis and were considered to be biologically plausible [55]. However, we cannot rule 
out the possibility that due to the number of comparisons made, we may have some 
estimates that are false positives.
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Ours is the first epidemiologic study to report an interaction between gene-specific promoter 
methylation levels in RARβ and PAH-DNA adducts in association with hormone receptor 
positive tumor subtype, suggesting that these may be important factors in tumor subtype 
differentiation. However, few other associations or interactions between adducts and 
methylation markers were observed. Better understanding of the factors that influence breast 
cancer subtype is crucial; tumor subtype is considered in treatment decisions and is 
associated with differences in survival. These results require replication and further 
investigation of the biological mechanism to better understand the implications to 
carcinogenesis.
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Table I
Age distributions by PAH-DNA adducts (detectable versus nondetectable) and case status, LIBCSP 
1996-1997.
Cases Controls
Detectable Nondetectable Detectable Nondetectable
Age Group N % N % N % N %
<40 12 5.3% 39 6.0% 26 8.9% 60 9.3%
40-50 53 23.2% 128 19.8% 80 27.3% 152 23.5%
50-60 49 21.5% 203 31.5% 81 27.6% 187 28.9%
60-70 55 24.1% 144 22.3% 68 23.2% 158 24.4%
70+ 59 25.9% 131 20.3% 38 13.0% 91 14.0%
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Table V
Age-adjusted ORs and 95%Cis for the association between detectable PAH-DNA adducts and global 
methylation markers using a control-only approach, LIBCSP 1996-1997.
Global Methylation Nondetectable Adducts (N) Detectable Adducts (N) Age-Adjusted OR (95% CI)
LUMA
    <0.56 142 325 1.00 (reference)
    ≥0.56 149 318 0.92 (0.70, 1.22)
LINE-1
    <78.7 154 305 1.00 (reference)
    ≥78.7 137 336 1.25 (0.94, 1.65)
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